drugset / Trial / NCT04322344
Escin in Patients With Covid-19 Infection
Phase 2/3
Unknown
120 enrolled
University of Catanzaro
Azienda Ospedaliera Pugliese Ciaccio · collabAzienda Ospedaliera Universitaria Mater Domini, Catanzaro · collab
Non-randomizedParallel-groupDouble-blindSupportive care
Summary
In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world. There is no specific drug treatment for this disease. Considering that lung damage is related to both viral infection and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on treatment to conventional antiviral drugs in COVID-19 infected patients.
Timeline
- Start
- 2020-03-23
- Primary completion
- 2020-06-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Escin | Unknown | 20 mg | Oral |
| Subject | Escin | Unknown | 40 mg | Oral |